NY-ESO-1 is a tumor-associated antigen (TAA) and expressed in approximately one-quarter to one-third of lung cancers, melanomas, ovarian cancers, esophageal cancers, bladder cancers, and prostate cancers, and its expression is associated with high-grade tumors. Here, CTAG1B is linked to prostate carcinoma.